Most clinical biochemists add further investigations when interpreting the results of laboratory analyses if they feel that doing so will either help to establish a diagnosis or assist patient management.We have recently called this practice 're£ective testing' since it is discretionary and based on the clinical judgement of biochemists, after taking into account information relevant to interpretation, such as age and sex of the patient, other results, and clinical information. 1 It depends on the knowledge and experience of individuals and in this respect di¡ers crucially from 're£ex testing', where algorithms generate additional tests automatically.
Re£ective testing has been the subject of vigorous debate recently, and it is pertinent to examine the substantive issues relating to this practice. Firstly, does it contribute to patient care? This issue is fundamental in determining whether or not re£ective testing is ethically responsible, yet its clinical value is virtually unknown. We have recently examined the clinical utility of re£ective testing with particular reference to vitamin D and iron studies, 1 but this is --perhaps surprisingly --the ¢rst attempt to examine it in a systematic way. Re£ective testing in this study did lead to changes in patient management, but we also wished to measure the e¡ectiveness of the practice. The method of assessment that we used --the number of add-on tests needed to obtain a diagnosis (NND) --is analogous to the number of patients who have to be treated in order to obtain a given bene¢t in therapeutics (NNT). Although in principle NND may help to assess individual clinical practice, its use is limited to straightforward clinical scenarios. The same method of assessment may also be applied to re£ex testing, and indeed may be used to compare the e¡ectiveness of re£ective and re£ex testing.We took the opportunity presented by our study to compare the e¡ectiveness of the re£ective testing practice of one of us (JRP) with a published study of re£ex testing, 2 with respect to diagnosing haemochromatosis. Our ¢nding --that JRP's re£ective testing was more e⁄cient than the re£ex testing strategy used --should not be surprising. Re£ective testing involves the use of more complex information than can easily be incorpo-rated into the algorithms that drive re£ex testing. A more suitable comparison may have been between a re-£ex testing strategy to which JRP had contributed, and his own re£ective testing practice.
If re£ective testing does contribute to patient care, is it always ethically responsible? Predictably, the debate about ethical aspects has focused on controversial areas, but there is consensus between professionals that re£ective testing which is clearly relevant to the presenting complaint or which expedites patient management is appropriate, but that it is unethical to add on investigations that are irrelevant. 3 There is more controversy about adding investigations that may explain abnormal biochemistry but which do not relate to the presenting complaint. Central to the ethical debate are issues such as patient consent and the relationships both between patients and their doctors, and between requesting clinicians and laboratory sta¡. In many instances, the consent given by individual patients for (relevant) investigations to be performed is implicit and depends heavily on the trust that exists between patients and their doctors. In a similar way, requesting clinicians implicitly trust laboratory sta¡ to practice re£ective testing in a clinically responsible way. The addition of tests that are di⁄cult to justify clinically not only leaves the reporting biochemist open to the charge of unethical practice, but importantly also damages the relationship of trust that normally exists between clinical and laboratory sta¡.
Re£ective testing is complementary to and closely linked with result interpretation. Both are likely to become the object of increasing scrutiny due to the need to provide cost-e¡ective improved clinical care and to reduce medical error. 4 Quality assurance of interpretation already exists. 5--7 Further studies are now required to establish which re£ective testing practices add value to patient care, and what patients and requesting clinicians think about re£ective testing in general.
Note
Since this Editorial was written, Dr Paterson has sadly died.
